Ingrezza
NDC Package 70370-1040-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Ingrezza is valbenazine is used to treat involuntary movements of the face, tongue, or other body parts (tardive dyskinesia). Marketed by Neurocrine Biosciences, Inc., this product is identified by NDC 70370-1040 and is authorized under FDA application NDA209241.

Identification & Billing

NDC Package Code
70370-1040-2
Package Description
90 CAPSULE in 1 BOTTLE
Product Code
70370-1040
11-Digit Billing Format
70370104002

Clinical Specifications

Proprietary Name
Ingrezza
Dosage Form
-
Usage Information
Valbenazine is used to treat involuntary movements of the face, tongue, or other body parts (tardive dyskinesia). This medication is thought to work by decreasing the amount of certain natural substances in the brain that affect how your nerves and muscles work (monoamines such as dopamine, serotonin, and norepinephrine).

Regulatory & Marketing

Labeler Name
Neurocrine Biosciences, Inc.
FDA Application #
NDA209241
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-20-2017
End Marketing Date
05-07-2021
Listing Expiration
05-07-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70370-1040). Click a package code to view its specific billing and regulatory data.

70370-1040-1
30 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70370-1040-2 identifies a specific commercial package of 90 capsule in 1 bottle of Ingrezza, labeled by Neurocrine Biosciences, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Neurocrine Biosciences, Inc. on April 20, 2017. The current certification is valid through May 07, 2021.

What are the primary indications for this medication?

Valbenazine is used to treat involuntary movements of the face, tongue, or other body parts (tardive dyskinesia). This medication is thought to work by decreasing the amount of certain natural substances in the brain that affect how your nerves and muscles work (monoamines such as dopamine, serotonin, and norepinephrine).

How is this Neurocrine Biosciences, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70370104002. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70370-1040-2
11-Digit CMS (5-4-2)
70370-1040-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.